FRANKFURT, April 28 (REUTERS) - German healthcare and materials group Merck KGaA MRCG.DE said on Monday it struck a deal to acquire U.S. biotech firm SpringWorks Therapeutics SWTX.O for an equity value of $3.9 billion to boost its cancer drug business.
Darmstadt, Germany-based Merck said in a statement that the purchase price of $47 per share in cash represents an equity value of about $3.9 billion, equivalent to an enterprise value of $3.4 billion (3.0 billion euros), when SpringWorks’ cash holdings are deducted.
(Reporting by Ludwig Burger; Editing by Kirsten Donovan)
((ludwig.burger@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.